title: Organizing pneumonia after rituximab therapy: Two cases.
abstract: Rituximab, a chimeric monoclonal antibody against CD20, very rarely causes lung toxicity. Clinical presentations include lung infiltrates, alveolar hemorrhage, and adult respiratory distress syndrome. Three cases of organizing pneumoinia (formerly called bronchiolitis obliterans with organizing pneumonia or BOOP) have been reported. In our experience, organizing pneumonia occurred in 2 of 25 patients treated with rituximab, for RA and Castleman's disease, respectively. Because organizing pneumonia may be asymptomatic, as illustrated by one of our cases, we recommend obtaining a chest radiograph routinely before rituximab re-treatment.
authors.affiliation: Rheumatology Department, Gabriel Montpied Teaching Hospital, Clermont-Ferrand, France. msoubrier@chu-clermontferrand.fr
authors.forename: Martin
authors.initials: M
authors.lastname: Soubrier
authors.forename: Gaëlle
authors.initials: G
authors.lastname: Jeannin
authors.forename: Jean Louis
authors.initials: JL
authors.lastname: Kemeny
authors.forename: Anne
authors.initials: A
authors.lastname: Tournadre
authors.forename: Nicolas
authors.initials: N
authors.lastname: Caillot
authors.forename: Denis
authors.initials: D
authors.lastname: Caillaud
authors.forename: Jean Jacques
authors.initials: JJ
authors.lastname: Dubost
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008875:Middle Aged; D011014:Pneumonia / Q000139:chemically induced* / Q000188:drug therapy; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D000069283:Rituximab